TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6370703
Drug: Enprofylline (E)
Normalized name: etofylline
DrugBank: Enprofylline (DB00824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline (E) 1.5 mg/kg
Study: 29849487
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (n = 43)
Study: 17768472
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% zinc sulphate solution
Study: 17768472
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% zinc sulphate solution
Study: 15514406
Drug: Citalopram, 10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram, 10-40 mg/day
Study: 11580079
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 mg/day for 2 years and then 10 mg/day for 1 year)
Study: 7633170
Drug: Ovum pickup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovum pickup at 36 hr after hCG injection (group B)
Study: 7633170
Drug: Ovum pickup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovum pickup at 35 hr after hCG injection (group A)
Study: 7633170
Drug: Ovum pickup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovum pickup at 37 hr after hCG injection (group C)
Study: 29183910
Drug: Intensifying treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensifying treatments to three oral agents or insulin regimens
Study: 29183910
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone use
Study: 20843375
Drug: Conventional dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dialysis solution (Stay.safe)
Study: 20843375
Drug: Neutral pH,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral pH, low GDP dialysis solution (Balance)
Study: 18993156
Drug: 16-week group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-week group-based aerobic high-intensity interval training model twice weekly for 65 to 80 minutes/day (n = 40)
Study: 17132385
Drug: Standardised advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised advice and a tapering off schedule with biweekly follow‐up visits (n = 73)
Study: 12932090
Drug: Five-day course
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day course of artesunate plus a 14-day course of high-dose primaquine (0.6 mg/kg, maximum dose = 30 mg) (Group A5 + P)
Study: 12932090
Drug: Seven-day course
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-day course of artesunate plus a 14-day course of high-dose primaquine (Group A7 + P)
Study: 12932090
Drug: High-dose primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose primaquine (0.6 mg/kg of base a day)
Study: 14747668
Drug: Diet providing
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet providing an ample protein intake (1.67 g. kg fat-free mass(‐1). d(‐1))
Study: 14747668
Drug: Diet approximating
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet approximating the mean minimum adult protein requirement (0.71 g. kg fat-free mass(‐1). d(‐1))
Study: 7760775
Drug: Elemental mercury
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental mercury exposure (mean urinary Hg = 36 micrograms/l)
Study: 21123958
Drug: Coping training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping training program with 14 weekly two-hour sessions
Study: 15126758
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (3 month course of a macrolide antibiotic, douche, and topical steroid)
Study: 11787915
Drug: Intravenous Syntocinon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Syntocinon (10 iu)
Study: 11787915
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (500 microg)
Study: 8196432
Drug: Primary functional
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary functional treatment without external or internal stabilization
Study: 31728714
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg/day for 11 days)
Study: 31728714
Drug: Lorlatinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib alone (50 mg, 75 mg, 100 mg)
Study: 28525543
Drug: Glucose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose placebo (12 g/d)
Study: 28525543
Drug: Fructan (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructan (12 g/d)
Study: 28525543
Drug: Galacto-oligosaccharides (GOS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galacto-oligosaccharides (GOS, 6 g/d)
Study: 28525543
Drug: Sorbitol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol (6 g/d)
Study: 19299839
Drug: Feldenkrais intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feldenkrais intervention (twice‐weekly group classes over 8 weeks)
Study: 24944159
Drug: Bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 500 mg/d
Study: 24944159
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg/d
Study: 23623755
Drug: Ramipril/HCTZ fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril/HCTZ fixed-dose combination (5/25 mg/d) - Group A (test formulation)
Study: 23623755
Drug: Ramipril/HCTZ fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril/HCTZ fixed-dose combination (5/25 mg/d) - Group B (reference formulation)
Study: 16996596
Drug: Subthreshold grid
Normalized name: MINERAL OIL 100 g in 100 mL TOPICAL LIQUID [THE GRID]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subthreshold grid laser treatment (SGLT)
Study: 29703633
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (50 mg of sodium ferrous citrate daily; oral group, n = 29)
Study: 29703633
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (40 mg of saccharated ferric oxide weekly; IV group, n = 32)
Study: 22917853
Drug: MAP0004 (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP0004 (3.0 mg, supratherapeutic dose)
Study: 17828038
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (200 mg of intravenous erythromycin twice daily + 10 mg of intravenous metoclopramide four times daily)
Study: 17828038
Drug: Erythromycin alone
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin alone (200 mg of intravenous erythromycin twice daily)
Study: 15142201
Drug: Intravenous lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lansoprazole in NaCl
Study: 15142201
Drug: Intravenous lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lansoprazole in polyethylene glycol
Study: 28414583
Drug: Varenicline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline and behavioral therapy
Study: 9147709
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg thrice daily
Study: 9147709
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg once daily
Study: 25332468
Drug: Leu-enriched essential
Normalized name: Leu
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leu-enriched essential amino acids (3.5 g of Leu)
Study: 9832483
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet
Study: 10489396
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet in hypertensive subjects
Study: 8942358
Drug: 15NH4Cl taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15NH4Cl taken orally every 20 min for 6 h (total 1.5 g)
Study: 1656145
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (1600 mg/day)
Study: 1656145
Drug: Baclofen (GABAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (GABAB agonist, 10(‐8)‐10(‐5) M)
Study: 1656145
Drug: Bicuculline (GABAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicuculline (GABAA antagonist)
Study: 19759186
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy with concurrent chemotherapy
Study: 17913002
Drug: Control formulations
Normalized name: nut.tx, weight loss-control formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formulations (various enzymes and antibacterial agents)
Study: 9106921
Drug: Conformal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conformal treatment with customized blocks, median high-dose volume (HDV) of 689 cm3
Study: 9106921
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with rectangular fields, median high-dose volume (HDV) of 792 cm3
Study: 8258043
Drug: Etidronate 10
Normalized name: etidronate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate 10 mg/kg/day
Study: 28738258
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (n=80)
Study: 28738258
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus chemotherapy (n=74)
Study: 16254147
Drug: High-dose DAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DAT (daunorubicin, cytarabine, and thioguanine)
Study: 9322479
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg plus metoclopramide 10 mg (Group M2)
Study: 30394347
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with dexmedetomidine (2 μg/mL)
Study: 24496455
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of oral anticoagulants
Study: 24496455
Drug: OAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC with antiplatelets (aspirin or clopidogrel)
Study: 15200742
Drug: Chlorhexidine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine 0.5% vaginal gel (CHX-VG), 2.5 g, daily for 7 days
Study: 15200742
Drug: Metronidazole vaginal
Normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole vaginal tablets 500 mg (M), daily for 7 days
Study: 15200742
Drug: Chlorhexidine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine 0.5% vaginal gel (CHX-VG)
Study: 9692706
Drug: Any gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any gastric antisecretory drug (mean duration 10.1 years, range 0.7-21 years)
Study: 29901296
Drug: 5-reductase inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-reductase inhibitor (5-ARI) Pentester 5 mg once daily
Study: 29901296
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 5-ARI (Penester 5 mg once daily) and blocker (Fokusin 0.4 mg once daily)
Study: 20123670
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (120 mg EGb 761 twice daily)
Study: 17187496
Drug: Estrogen as
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen as an adjunct to standard antipsychotic medication
Study: 15713726
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with alendronate and hormone replacement therapy
Study: 12016085
Drug: Shock wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock wave therapy (1000 impulses at 14 kV)
Study: 10560786
Drug: Transdermal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐estradiol (50 microg/day, transdermal) and norethisterone acetate (2.5 mg/day, orally)
Study: 10560786
Drug: Transdermal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐estradiol
Study: 8919710
Drug: Carbamazepine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (400 to 800 mg, mean 683 mg)
Study: 1871801
Drug: CsA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA and steroids alone
Study: 31271526
Drug: Etanercept and
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept and methotrexate in combination
Study: 28841667
Drug: D-aspartic acid
Normalized name: (3S)-3-methyl-D-aspartic acid
DrugBank: D-Aspartic Acid (DB02655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-aspartic acid (6 g/d)
Study: 19776136
Drug: Only 500
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only 500 mL skim milk/d (M)
Study: 7491044
Drug: Neither treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither treatment (control group)
Study: 8279224
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen exposure (2.8 atm, 100% O2, 60 min daily for 10 days)
Study: 3519240
Drug: 0.170 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.170 mg/kg bambuterol b.i.d.
Study: 3291897
Drug: Pinacidil or
Normalized name: pinacidil Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil or hydralazine as monotherapy or with propranolol and/or hydrochlorothiazide
Study: 12621507
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir 500 mg twice daily until resolution of neutropenia
Study: 12621507
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 600 mg every 6 h until resolution of neutropenia or acyclovir 125 mg/m(2) intravenously every 6 h
Study: 3807474
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg piretanide with 40 mg hyoscine‐N‐butylbromide (HNB)
Study: 3807474
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg piretanide without HNB
Study: 16431002
Drug: Kaneka Q10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaneka Q10 300 mg/day
Study: 16431002
Drug: Kaneka Q10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaneka Q10 600 mg/day
Study: 7901059
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 g oral dose)
Study: 3528725
Drug: Naftidrofurylhydrogenoxalate (Dusodril)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofurylhydrogenoxalate (Dusodril) as adjunctive therapy
Study: 3528725
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dextran‐40 infusions)
Study: 23410527
Drug: Aromatherapy inhalation
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy inhalation
Study: 8911878
Drug: Octreotide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (50 micrograms three times daily, total dose 150 micrograms)
Study: 8911878
Drug: Octreotide (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (62.5 micrograms continuous infusion 24/h)
Study: 8911878
Drug: Octreotide (112.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (112.5 micrograms continuous infusion 24/h)
Study: 8911878
Drug: Octreotide (113
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (113 micrograms continuous infusion)
Study: 8911878
Drug: Octreotide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (all doses)
Study: 1816439
Drug: Captopril, 50
Normalized name: Captopril, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 50 mg
Study: 1816439
Drug: Prazosin, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin, 2 mg
Study: 2455105
Drug: Nifedipine, 20
Normalized name: Nifedipine, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 20 mg
Study: 6125198
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release aminophylline tablets
Study: 6125198
Drug: Inhaled rimiterol
Normalized name: rimiterol
DrugBank: Rimiterol (DB13559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled rimiterol
Study: 27914903
Drug: Short-term psychoanalytical
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychoanalytical therapy
Study: 14991686
Drug: Bromazepam 6
Normalized name: bromazepam 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam 6 mg from Medley SA Indústria Farmacêutica (test formulation)
Study: 11713622
Drug: 0.0 mg
Normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 mg (placebo)
Study: 7491369
Drug: Imipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (150 mg/day for at least 4 consecutive weeks)
Study: 535860
Drug: Piracetam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (10 g i.v./h)
Study: 535860
Drug: Laevulose (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laevulose (placebo infusion)
Study: 20456192
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin 0.1%
Study: 9422303
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with lidocaine 50 mg/ml 1.5‐2 ml in 7.5% glucose through a 27‐G Quincke needle (Group S)
Study: 9422303
Drug: Propofol anaesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anaesthesia with a bolus induction of 2 mg/kg followed by infusion (Group P)
Study: 8284627
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tetracycline 2 g, metronidazole 750 mg, bismuth subsalicylate 5 or 8 tablets) plus ranitidine 300 mg
Study: 8284627
Drug: Ranitidine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine alone 300 mg
Study: 29458317
Drug: 1 kcal/mL
Normalized name: lactose-reduced food 0.06 gram-1 kcal/mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 kcal/mL enteral nutrition formulation
Study: 10406828
Drug: Glyburide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (20 mg/d)
Study: 8926537
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of red pepper
Study: 8926537
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of red pepper with propranolol
Study: 7107086
Drug: Spironothiazid (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironothiazid (50 mg spironolactone, 50 mg hydrochlorothiazide)
Study: 7107086
Drug: Aldactone dragees
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldactone dragees (50 mg) plus Esidrex tablets (25 mg)
Study: 29654023
Drug: Erlotinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib monotherapy
Study: 30293332
Drug: Single aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single aspirin
Study: 9180622
Drug: Active biofeedback
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active biofeedback treatment
Study: 17584007
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg daily for 4 days prior to hypoxia exposure
Study: 9474534
Drug: Complete denture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete denture therapy procedures
Study: 9474534
Drug: Procedural research
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Procedural research in denture therapy
Study: 7857356
Drug: pidotimod 400
Normalized name: pidotimod 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pidotimod 400 mg
Study: 2509605
Drug: MOR‐22 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR‐22 and UFT (or FT‐207) in combination
Study: 145237
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc
Study: 26280756
Drug: Canagliflozin 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 25, 100, 200, or 400 mg (single dose and repeated doses for 14 days)
Study: 22983502
Drug: Strengthening ties
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengthening ties that provide social support but not drug support
Study: 22983502
Drug: Reducing ties
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reducing ties that provide both drug and social support
Study: 17045558
Drug: Six-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-dose regimen of artemether-lumefantrine
Study: 12938592
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled intravenous morphine
Study: 16422731
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs
Study: 21154265
Drug: L-arginine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (8 g/day)
Study: 10716474
Drug: Training group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training group (daily handgrip training)
Study: 10716474
Drug: L-arginine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine + Training
Study: 1490801
Drug: Trapidil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapidil (200 mg orally, 100 mg intravenously)
Study: 3987781
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg) before standardized breakfast (Phase A)